Lexicon Pharmaceuticals, Inc.
LXRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $67 | $22 | $46 | $64 |
| Short-Term Investments | $171 | $148 | $92 | $23 |
| Receivables | $3 | $1 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $5 | $5 | $2 | $2 |
| Total Curr. Assets | $246 | $177 | $141 | $89 |
| Property Plant & Equip (Net) | $7 | $8 | $8 | $3 |
| Goodwill | $45 | $45 | $45 | $45 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $1 | $0 | $0 |
| Total NC Assets | $52 | $53 | $53 | $48 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $298 | $229 | $194 | $137 |
| Liabilities | – | – | – | – |
| Payables | $15 | $14 | $10 | $9 |
| Short-Term Debt | $1 | $1 | $1 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $29 | $16 | $11 | $12 |
| Total Curr. Liab. | $45 | $32 | $23 | $22 |
| LT Debt | $107 | $105 | $54 | $1 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $107 | $105 | $54 | $1 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $8 | $7 | $7 | $2 |
| Total Liabilities | $152 | $136 | $77 | $23 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,967 | -$1,767 | -$1,590 | -$1,488 |
| AOCI | $0 | $0 | -$0 | -$0 |
| Other Equity | $2,113 | $1,860 | $1,707 | $1,601 |
| Total Equity | $146 | $93 | $117 | $114 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $298 | $229 | $194 | $137 |
| Net Debt | $42 | $84 | $9 | -$62 |